Beta Bionics (BBNX) Stock Price, News & Analysis

Company Overview

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Key Stats

• Today's Range: $11.15 to $11.75
• 50-Day Range: $9.71 to $20.98
• 52-Week Range: $8.89 to $24.50
• Volume: 176,370 shs
• Average Volume: 469,563 shs
• Market Capitalization: $492.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.83
• Consensus Rating: Moderate Buy

BBNX Stock Analysis - Frequently Asked Questions

How have BBNX shares performed this year?

Beta Bionics' stock was trading at $23.81 at the beginning of 2025. Since then, BBNX shares have decreased by 50.3% and is now trading at $11.83.
View the best growth stocks for 2025 here.

How were Beta Bionics' earnings last quarter?

Beta Bionics, Inc. (NASDAQ:BBNX) released its quarterly earnings results on Tuesday, March, 25th. The company reported ($1.82) earnings per share for the quarter, missing the consensus estimate of ($0.42) by $1.40. The company had revenue of $20.44 million for the quarter, compared to analyst estimates of $20.01 million.
Read the conference call transcript.

When did Beta Bionics IPO?

Beta Bionics (BBNX) raised $204 million in an initial public offering on Thursday, January 30th 2025. The company issued 12,000,000 shares at a price of $17.00 per share.

When does the company's lock-up period expire?

Beta Bionics' lock-up period expires on Tuesday, July 29th. Beta Bionics had issued 12,000,000 shares in its initial public offering on January 30th. The total size of the offering was $204,000,000 based on an initial share price of $17.00. After the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Who are Beta Bionics' major shareholders?

Beta Bionics' top institutional shareholders include Jennison Associates LLC (0.16%), Evanson Asset Management LLC (0.09%), Values First Advisors Inc. (0.09%) and Bank of New York Mellon Corp (0.06%). Insiders that own company stock include Hadley Harbor Aggre Wellington and Mike Mensinger.
View institutional ownership trends.

How do I buy shares of Beta Bionics?

Shares of BBNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 3/25/2025
• Today: 5/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BBNX
• Previous Symbol: NASDAQ:BBNX
• CIK: 1674632
• Web: N/A
• Phone: (949) 427-7785
• Fax: N/A
• Employees: 294
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $24.83
• High Stock Price Target: $30.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +109.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $65.12 million
• Price / Sales: 7.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 43,349,000
• Free Float: N/A
• Market Cap: $512.82 million
• Optionable: N/A
• Beta: N/A